AmgenAMGNEarnings & Financial Report
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
AMGN Q1 FY2026 Key Financial Metrics
Revenue
$8.6B
Gross Profit
$5.9B
Operating Profit
$2.7B
Net Profit
$1.8B
Gross Margin
68.2%
Operating Margin
30.9%
Net Margin
21.1%
YoY Growth
5.8%
EPS
$3.34
Amgen Q1 FY2026 Financial Summary
Amgen reported revenue of $8.6B (up 5.8% YoY) for Q1 FY2026, with a net profit of $1.8B (21.1% margin). Cost of goods sold was $2.7B, operating expenses totaled $3.2B.
Key Financial Metrics
| Total Revenue | $8.6B |
|---|---|
| Net Profit | $1.8B |
| Gross Margin | 68.2% |
| Operating Margin | 30.9% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
Amgen Q1 FY2026 revenue of $8.6B breaks down across 2 segments, led by Product sales at $8.2B (95.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Product sales | $8.2B | 95.4% |
| Other revenues | $400.0M | 4.6% |
Amgen Annual Revenue by Year
Amgen annual revenue history includes year-by-year totals (for example, 2025 revenue was $36.8B).
Amgen Quarterly Revenue & Net Profit History
Amgen results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $8.6B | +5.8% | $1.8B | 21.1% |
| Q4 FY2025 | $9.9B | +8.6% | $1.3B | 13.5% |
| Q3 FY2025 | $9.6B | +12.4% | $3.2B | 33.7% |
| Q2 FY2025 | $9.2B | +9.4% | $1.4B | 15.6% |
| Q1 FY2025 | $8.1B | +9.4% | $1.7B | 21.2% |
| Q4 FY2024 | $9.1B | +10.9% | $627.0M | 6.9% |
| Q3 FY2024 | $8.5B | +23.2% | $2.8B | 33.3% |
| Q2 FY2024 | $8.4B | +20.1% | $746.0M | 8.9% |
Income Statement
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.39B | $8.50B | $9.09B | $8.15B | $9.18B | $9.56B | $9.87B | $8.62B |
| YoY Growth | 20.1% | 23.2% | 10.9% | 9.4% | 9.4% | 12.4% | 8.6% | 5.8% |
Balance Sheet
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $90.91B | $90.88B | $91.84B | $89.37B | $87.90B | $90.14B | $90.59B | $92.50B |
| Liabilities | $84.98B | $83.36B | $85.96B | $83.16B | $80.47B | $80.52B | $81.93B | $83.31B |
| Equity | $5.92B | $7.53B | $5.88B | $6.21B | $7.43B | $9.62B | $8.66B | $9.19B |
Cash Flow
| Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $2.46B | $3.57B | $4.77B | $1.39B | $2.28B | $4.68B | $1.60B | $2.19B |